AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Low interleukin-4 levels predict failure of antibiotics for H. pylori.
2003 FEB 12 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Patients with an impaired mucosal immune response fail treatment for Helicobacter pylori infection significantly more often than similar patients whose immune responses are normal, according to a report in the American Journal of Gastroenterology.
"Effective eradication of Helicobacter pylori infection has often proved more difficult than expected," commented Tom Borody and colleagues at the Centre for Digestive Diseases in Sydney and the University of Newcastle and Vasse Research Institute in Newcastle, Australia. "Antimicrobial resistance incompletely explains eradication failure. This study tests the hypothesis that an impaired immune response may contribute to failed eradication after standard antibiotic therapy."
Borody and his collaborators measured the production of gamma interferon (IFN-gamma) and interleukin-4 (IL-4) as surrogate markers of mucosal Th1 and Th2 immune responses, respectively, in 52 dyspeptic patients and 11 patients who had failed previous treatment for H. pylori infection.
The levels of IFN-gamma were similar in the two groups of patients. However, IL-4 production was significantly lower in both stimulated and unstimulated cultures for the group of patients who had failed previous therapy.
"Low levels of IL-4 secretion were detected irrespective of the number of courses of antibiotic therapy," reported Borody and his associates.
Levels of IgG antibodies specific for H. pylori in serum and saliva of the patients whose antibiotic regimen was not effective was lower than in ...
- ADHD treatment less risky than nontreatment: the risk for substance abuse in...
- Magazine article from: Clinical Psychiatry News Worcester, Sharon June 1, 2006 700+ words
...that the risk for substance abuse in untreated patients was 75%, compared with 25% in...and becoming pregnant by age 15. Untreated patients generally have intercourse earlier...driving simulation tests of treated and untreated patients. Reports analyzing national highway...
- Florida is State With Highest Percentage of Untreated Patients With Chronic...
- Newspaper article from: Biotech Week September 10, 2008 700+ words
...healthcare issues, finds that Florida has 1.2 million untreated patients with chronic obstructive pulmonary disease. This number...smaller states compared with Florida's 1.2 million untreated patients. The result of this under-treatment is that significant...
- The International Myeloma Foundation Applauds Expansion of VELCADE(R) for...
- Press release article from: Business Wire September 29, 2008 700+ words
...heralded the expansion of treatment options for previously untreated patients with multiple myeloma, giving patients in Canada and...outside of the U.S. to give new hope for previously untreated patients with multiple myeloma." Myeloma, also called multiple...
- TRIPLE THERAPY IN PREVIOUSLY UNTREATED PATIENTS REDUCES VIRAL LOAD BELOW LIMIT...
- Press release article from: PR Newswire July 9, 1996 700+ words
...an international randomized, double-blind, placebo- controlled trial, investigated VIRAMUNE in previously untreated patients. The twelve month results from this study compared the combinations of AZT, ddI and VIRAMUNE; AZT and ddI...
- The International Myeloma Foundation Says Previously Untreated Patients Could...
- Press release article from: Business Wire June 23, 2008 700+ words
...relapsed patients who have had at least one prior therapy. The FDA has now granted the use of VELCADE to previously untreated patients with multiple myeloma. The VELCADE approval is based on positive data from the international VISTA trial of VELCADE...
- Drug Combinations Containing Ziagen(TM) Effective for 72 Weeks In Some...
- Press release article from: PR Newswire June 29, 1998 700+ words
...transcriptase inhibitors. Data from 16-week surrogate endpoint studies have suggested that in some previously untreated patients, regimens containing Ziagen have a level of antiviral activity often associated with those containing a protease...
- ILEX Announces CAMPATH Front-Line CLL Study Fully Enrolled; Trial Will Evaluate...
- Press release article from: Business Wire June 23, 2004 700+ words
...evaluate the efficacy of CAMPATH(R) (alemtuzumab) versus chlorambucil as front-line therapy in previously untreated patients with progressive B-cell chronic lymphocytic leukemia (B-CLL). CAMPATH was granted accelerated approval...
- Preliminary Results of a Study with Nipent(R), Rituxan(TM) and Cyclophosphamide...
- Press release article from: PR Newswire November 14, 2003 700+ words
SuperGen, Inc. announced today that preliminary data from a clinical study of the anticancer compound Nipent(R) (pentostatin for injection), in combination therapy, reveal a response rate of 100 percent in patients with B-chronic lymphocytic leukemia (B-CLL). The interim results from this study,
Source: HighBeam Research, Low interleukin-4 levels predict failure of antibiotics for H. pylori.